The global market for cancer stem cells should grow from $2.1 billion in 2021 to $4.4 billion by 2026, at a compound annual growth rate (CAGR) of 16.1% for the period of 2021-2026.
The cancer stem cells market for breast cancer should grow from $429.6 million in 2021 to $940.6 million by 2026, at a CAGR of 17.0% for the period of 2021-2026.
The cancer stem cells market for prostate cancer should grow from $378.3 million in 2021 to $913.2 million by 2026, at a CAGR of 19.3% for the period of 2021-2026.
Report Scope
This research report presents an in-depth analysis of the global cancer stem cells market by cancer type and geographic markets. The report includes key inhibitors that affect various factors that help in growth of cancer stem cells. The report discusses the roles of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cancer stem cells market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and geographies such as the U.S., Europe and China.
The cancer stem cells market is mainly segmented into two major components: cancer type and geography. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, prostate cancer, brain cancer, bone cancer and other types of cancer. The market is segmented by geography into North America, Europe, Asia-Pacific and RoW.
The Report Includes
- 50 tables
- An overview of the global market and technologies for cancer stem cells
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Coverage of history, synthesis, isolation, identification and characteristics of cancer stem cells, and description of stem cell transplant types i.e., autologous, allogeneic, and syngeneic
- Detailed description of cancer stem cells, its pathophysiology and affects and major advancement of the industry and discussion on side effects of stem cells implantation
- Discussion on the future of stem cells for the treatment of COVID-19 and information about advancing stem cells to mainstream medicines for COVID-19
- Assessment of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players of the industry including AdnaGen AG, Advanced Cell Diagnostics Inc., BioNTech, Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Silicon Biosystems and ViaCyte Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Report?
- Scope of Report
- Information Sources and Methodology
- Intended Audience
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Market Definition and Scope
- History of Cancer Stem Cells
- Synthesis, Isolation and Identification of CSCs
- Characteristics of Cancer Stem Cells
- Metastasizing Tumor Cells
- Apoptosis
- Resistance to Chemotherapy
- Stem Cell Classification
- Based on Ability to Differentiate
- Based on Source
- Mechanism of Action
- Targeting Signaling Pathways
- Targeting CSCs Markers
- Targeting miRNA Expression
- Targeting CSCs' Niche
- Stem Cell Transplants
- Autologous
- Allogeneic
- Syngeneic
- Cancer Stem Cell Clinical Pipeline
Chapter 4 Market Dynamics
- Market Dynamics
- Drivers
- Increase in Cancer Research Activities
- Increase in Incidence and Mortality Rate of Cancer
- Restraints
- Ethical Issues
- High Cost Associated with Cancer Stem Cell Therapeutics
- Opportunity
- Increasing Cancer Stem Cell Research
- Successful Implementation of CSC as a Therapeutic Tool in Animals
Chapter 5 Market Breakdown by Cancer Type
- Lung Cancer
- Incidence of Lung Cancer
- Risk Factors
- Types of Lung Cancer
- Site of Lung Tumor Initiation
- Lung Cancer Stem Cells as Therapeutic Targets
- Breast Cancer
- Incidence and Mortality Rate of Breast Cancer
- Types of Breast Cancer
- Site of Tumor Initiation
- Breast Cancer Stem Cells as Therapeutic Targets
- Colorectal Cancer
- Incidence and Mortality of Colorectal Cancer
- Colorectal Cancer Stem Cells as Therapeutic Targets
- Leukemia
- Incidence and Mortality of Leukemia
- Leukemia Stem Cells as Therapeutic Targets
- Melanoma
- Incidence and Mortality of Melanoma
- Melanoma Cancer Stem Cells as Therapeutic Targets
- Prostate Cancer
- Incidence and Mortality Rate of Prostate Cancer
- Prostate Cancer Stem Cells as Therapeutic Targets
- Brain Cancer
- Incidence of Brain Cancer
- Brain Cancer Stem Cells as Therapeutic Targets
- Bone Cancer
- Bone Cancer Stem Cells as Therapeutic Targets
- Others
Chapter 6 Market Breakdown by Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- Rest of the World (RoW)
- Brazil
- GCC Countries
- Rest of the World Countries
Chapter 7 COVID-19 and Stem Cell Research
- Impact of Early-Stage Research
- Advancing Stem Cells to Mainstream Medicines for COVID-19
- The Future of Stem Cells for the Treatment of COVID-19
Chapter 8 Cost of Stem Cell Therapy in 2021
- Types of Stem Cell Therapy
- Stem Cell Therapy is Expensive - Why?
- Ethics and Regulations for Stem Cell Therapy
Chapter 9 Competitive Landscape
- Global Company Ranking Analysis
- Start-up on Regenerative Therapeutics or Stem Cell Therapeutics
Chapter 10 Company Profiles
- Adnagen Ag
- Advanced Cell Diagnostics Inc.
- Apceth Biopharma
- Aviva Biosciences Corp.
- BioNTech
- Benitec Biopharma
- Caladrius Biosciences
- Celgene Corp.
- Epic Sciences Inc.
- Excellthera
- Fluxion Biosciences Inc.
- Galena Biopharma
- Gamida Cell
- Genexine
- Geron
- Immunocellular Therapeutics
- Oncocyte Corp.
- Oncomed Pharmaceuticals Inc.
- Pluristem Therapeutics Inc.
- Silicon Biosystems S.P.A
- Sphere Fluidics Ltd.
- Viacyte Inc.
- Vitatex Inc.
Chapter 11 List of Patents
- North American Patents on Cancer Stem Cells
- European Patents on Cancer Stem Cells
- Asia-Pacific Patents on Cancer Stem Cells
- RoW Patents on Cancer Stem Cells
Chapter 12 Appendix: Acronyms
List of Tables
Summary Table: Global Market for Cancer Stem Cells, by Cancer Type, Through 2026
Table 1: Clinical Trials on Cancer Stem Cells
Table 2: Global Market for Cancer Stem Cells, by Cancer Type, Through 2026
Table 3: Global Market for Cancer Stem Cells for Lung Cancer, by Region, Through 2026
Table 4: Global Market for Cancer Stem Cells for Breast Cancer, by Region, Through 2026
Table 5: Global Market for Cancer Stem Cells for Colorectal Cancer, by Region, Through 2026
Table 6: Global Market for Cancer Stem Cells for Leukemia, by Region, Through 2026
Table 7: Global Market for Cancer Stem Cells for Melanoma, by Region, Through 2026
Table 8: Global Market for Cancer Stem Cells for Prostate Cancer, by Region, Through 2026
Table 9: Global Market for Cancer Stem Cells for Brain Cancer, by Region, Through 2026
Table 10: Global Market for Cancer Stem Cells for Bone Cancer, by Region, Through 2026
Table 11: Global Market for Cancer Stem Cells for Other Cancers, by Region, Through 2026
Table 12: Global Market for Cancer Stem Cells, by Region, Through 2026
Table 13: North American Market for Cancer Stem Cells, by Country, Through 2026
Table 14: North American Market for Cancer Stem Cells, by Cancer Type, Through 2026
Table 15: European Market for Cancer Stem Cells, by Country, Through 2026
Table 16: European Market for Cancer Stem Cells, by Cancer Type, Through 2026
Table 17: Asia-Pacific Market for Cancer Stem Cells, by Country, Through 2026
Table 18: Asia-Pacific Market for Cancer Stem Cells, by Cancer Type, Through 2026
Table 19: RoW Market for Cancer Stem Cells, by Country/Region, Through 2026
Table 20: RoW Market for Cancer Stem Cells, by Cancer Type, Through 2026
Table 21: Countries Where Stem Cell Research is Most Prevalent
Table 22: Adnagen: Product Portfolio
Table 23: Advanced Cell Diagnostics: Product Portfolio
Table 24: Apceth Biopharma: Product Portfolio
Table 25: Aviva Biosciences: Product Portfolio
Table 26: BioNTech: Product Portfolio
Table 27: Benitec Biopharma: Product Portfolio
Table 28: Caladrius Biosciences: Product Portfolio
Table 29: Celgene Corp.: Product Portfolio
Table 30: Epic Sciences: Product Portfolio
Table 31: ExCellThera: Product Portfolio
Table 32: Fluxion Biosciences: Product Portfolio
Table 33: Galena Biopharma: Product Portfolio
Table 34: Gamida Cell: Product Portfolio
Table 35: Genexine: Product Portfolio
Table 36: Geron: Product Portfolio
Table 37: ImmunoCellular Therapeutics: Product Portfolio
Table 38: OncoCyte: Product Portfolio
Table 39: OncoMed: Product Portfolio
Table 40: Pluristem Therapeutics: Product Portfolio
Table 41: Silicon Biosystems: Product Portfolio
Table 42: Sphere Fluidics: Product Portfolio
Table 43: ViaCyte Inc.: Product Portfolio
Table 44: Vitatex: Product Portfolio
Table 45: List of North American Patents on Cancer Stem Cells
Table 46: List of European Patents on Cancer Stem Cells
Table 47: List of Asia-Pacific Patents on Cancer Stem Cells
Table 48: List of Row Patents on Cancer Stem Cells
Table 49: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market Shares of Cancer Stem Cell, by Cancer Type, 2020
Figure 1: Classification of Stem Cells Based on Source
Figure 2: Classification of Stem Cells Based on Source and Marker
Figure 3: Total Cost per Capita of Cancer in Europe (Direct, Indirect and Informal Costs in Each Country), 2018
Figure 4: Incidence of Cancer, 2020
Figure 5: Mortality of Cancer, 2020
Figure 6: Major Issue in Stem Cell Research in Iran, 2017
Figure 7: Number of New Cancer Cases and Mortality Rates Worldwide, by Cancer Type 2020
Figure 8: Global Segmentation of the Market for Cancer Stem Cells, by Cancer Type
Figure 9: Global Market Shares of Cancer Stem Cells, by Cancer Type, 2020
Figure 10: Distribution of New Cases of Lung and Bronchus Cancer, by Age Group, 2020
Figure 11: Global Market for Lungs Cancer in Cancer Stem Cells, by Region, 2019-2026
Figure 12: Distribution of Female Breast Cancer Cases, by Stage at Diagnosis
Figure 13: Breast Cancer Rates in Top Countries, 2020
Figure 14: Global Market for Cancer Stem Cells for Breast Cancer, by Region, 2019-2026
Figure 15: Incidence of Colorectal Cancer Among More and Less Developed Regions, 2018
Figure 16: Global Market for Cancer Stem Cells for Colorectal Cancer, by Region, 2019-2026
Figure 17: Incidence and Mortality Rates of Leukemia in the U.S., 2010-2019
Figure 18: Global Market for Cancer Stem Cells for Leukemia, by Region, 2019-2026
Figure 19: Incidence and Mortality Rates of Melanoma in U.S., 2010-2019
Figure 20: Global Market for Cancer Stem Cells for Melanoma, by Region, 2019-2026
Figure 21: Distribution of New Cases of Melanoma in the U.S., by Age Group, 2021
Figure 22: Global Market for Cancer Stem Cells for Prostate Cancer, by Region, 2019-2026
Figure 23: Global Market for Cancer Stem Cells for Brain Cancer, by Region, 2019-2026
Figure 24: Global Market for Cancer Stem Cells for Bone Cancer, by Region, 2019-2026
Figure 25: Global Market for Cancer Stem Cells for Other Types of Cancer, by Region, 2019-2026
Figure 26: Global Market Shares of Cancer Stem Cells, by Region, 2020
Figure 27: Five Most Common Sites for Estimated New Cancer Cases and Death in U.S., 2021
Figure 28: North American Market Shares of Cancer Stem Cells, by Cancer Type, 2020
Figure 29: New Cases of Cancer in Males in the U.S., 2020
Figure 30: New Cases of Cancer in Females in the U.S., 2020
Figure 31: U.S. Market for Cancer Stem Cells, 2019-2026
Figure 32: Distribution of New Cancer Cases in Canada, 2021
Figure 33: Canadian Market for Cancer Stem Cells, 2019-2026
Figure 34: Cancer Incidence and Mortality in Mexico, 2021
Figure 35: Mexican Market for Cancer Stem Cells, 2019-2026
Figure 36: Predicted Cancer Mortality in Europe, 2021
Figure 37: European Market Shares of Cancer Stem Cells, by Cancer Type, 2020
Figure 38: Cancer Incidence and Mortality in Germany, 2020
Figure 39: German Market for Cancer Stem Cells, 2019-2026
Figure 40: Cancer Incidence and Mortality in France, 2018
Figure 41: French Market for Cancer Stem Cells, 2019-2026
Figure 42: Cancer Incidence in the U.K., 2018
Figure 43: U.K. Market for Cancer Stem Cells, 2019-2026
Figure 44: Cancer Incidence in Italy, 2020
Figure 45: Italian Market for Cancer Stem Cells, 2019-2026
Figure 46: Cancer Incidence in Spain, 2018
Figure 47: Spanish Market for Cancer Stem Cells, 2019-2026
Figure 48: Rest of European Market for Cancer Stem Cells, 2019-2026
Figure 49: Shares of Top Five Countries with Cancer Cases in Asia, 2018
Figure 50: Cancer Incidence in Southeast Asia, 2020
Figure 51: Asia-Pacific Market Shares of Cancer Stem Cell, by Cancer Type, 2020
Figure 52: Cancer Incidence in Japan, by Cancer Type, 2020
Figure 53: Cancer Deaths in Japan, by Cancer Type, 2020
Figure 54: Budget to Control Cancer in Japan, 2003-2015
Figure 55: Japanese Market for Cancer Stem Cells, 2019-2026
Figure 56: Cancer Incidence and Mortality in China, 2020
Figure 57: Chinese Market for Cancer Stem Cells, 2019-2026
Figure 58: Cancer Incidence and Mortality in Australia, 2020
Figure 59: Australian Market for Cancer Stem Cells, 2019-2026
Figure 60: Cancer Incidence and Mortality in India, 2020
Figure 61: Indian Market for Cancer Stem Cells, 2019-2026
Figure 62: Rest of Asia-Pacific Market for Cancer Stem Cells, 2019-2026
Figure 63: Distribution of New Cancer Cases in Latin America and the Caribbean, by Cancer Type, 2020
Figure 64: Distribution of Cancer Deaths in Latin America and the Caribbean, by Cancer Type, 202
Figure 65: RoW Market Shares of Cancer Stem Cells, by Cancer Type, 2020
Figure 66: Cancer Incidence and Mortality in Brazil, 2020
Figure 67: Brazilian Market for Cancer Stem Cells, 2019-2026
Figure 68: Brazilian Market for Cancer Stem Cells, 2019-2026
Figure 69: Most Common Cancer Cases in Qatar, by Incidence and Mortality, 2020
Figure 70: GCC Countries Market for Cancer Stem Cells, 2019-2026
Figure 71: Other Countries Market for Cancer Stem Cells, 2019-2026
Figure 72: Using MSC Therapy in COVID-19 Patients
Figure 73: How Much Does Stem Cell Therapy Cost?
Figure 74: Global Ranking in the Market for Cancer Stem Cells, by Pharmaceutical Company, 2020
Figure 75: Global Ranking in the Market for Cancer Stem Cells, by Start-up Pharmaceutical Company, 2020
Executive Summary
Cancer stem cells (CSCs) have properties similar to those of normal stem cells and have the ability to produce all the cell types found in a single type of cancer. These cells are tumorigenic and have the ability to generate tumors through self-renewal and differentiation. CSCs are believed to occur in tumors as a distinct population and produce new tumors by relapse and metastasis. Therefore, the development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease. Cancer stem cells are rare forms of immortal cells that occur in a tumor, and they give rise to many cell types that constitute the tumor. These cells have been found in a range of human tumors and a potential cancer treatment approach has been to use them as targets. Most anticancer therapies inhibit cancer cell growth by causing cancer cells to die. Although these treatments appear to be successful, the disease reoccurs in some cases.
Major factors contributing to the market growth are a rise in the incidence and mortality rate of cancer worldwide and increased R&D activities associated with the development of these therapies. The rise in the incidence of cancer globally has increased the need for a reliable and effective therapy that will completely eliminate the cancer cells in the body and reduce the risk of relapse or metastasis in the patient. Thus, there is a rise in both cancer research activities and in funding for the advancement of treatment technology. The rise in R&D activities will help to improve the knowledge of the researchers regarding CSCs and how these cells can be used as targets to improve the efficiency of conventional cancer therapies. However, ethical issues related to stem cells and the high costs related to cancer stem cell therapeutics could hamper the market growth. Successful implementation of CSCs therapeutics in animal models during preclinical trials will help to open new avenues for market growth.
According to the International Agency for Research on Cancer (IARC), in 2020, almost 19.2 million new cancers were diagnosed worldwide, and the global mortality rate due to cancer was around 10 million. Lung cancer was the leading cause of cancer among new cancer cases diagnosed in 2020, and it had the highest mortality rate for cancer cases worldwide among both men and women; however, breast cancer is the most commonly diagnosed cancer case and cause of death among women, accounting for approximately 12% of cancer deaths in females. It is also observed that minimum survival chances are observed in people with stomach and liver cancer.
Companies Mentioned
- Adnagen Ag
- Advanced Cell Diagnostics Inc.
- Apceth Biopharma
- Aviva Biosciences Corp.
- Benitec Biopharma
- BioNTech
- Caladrius Biosciences
- Celgene Corp.
- Epic Sciences Inc.
- Excellthera
- Fluxion Biosciences Inc.
- Galena Biopharma
- Gamida Cell
- Genexine
- Geron
- Immunocellular Therapeutics
- Oncocyte Corp.
- Oncomed Pharmaceuticals Inc.
- Pluristem Therapeutics Inc.
- Silicon Biosystems S.P.A
- Sphere Fluidics Ltd.
- Viacyte Inc.
- Vitatex Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 206 |
| Published | December 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 2.1 Billion |
| Forecasted Market Value ( USD | $ 4.4 Billion |
| Compound Annual Growth Rate | 16.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
